Moleculin Raises $8.3 Million Through Warrant Exercise

Got story updates? Submit your updates here. ›

Moleculin Biotech, Inc., a Phase 3 clinical stage pharmaceutical company, announced that it has entered into agreements with certain holders of its existing warrants to exercise those warrants, raising approximately $8.3 million in gross proceeds. The company will use the funds for working capital and general corporate purposes as it continues development of its pipeline of therapeutic candidates targeting hard-to-treat tumors and viruses.

Why it matters

This capital raise will provide Moleculin with additional resources to advance its clinical programs, including the ongoing MIRACLE trial evaluating its lead drug candidate Annamycin for the treatment of relapsed or refractory acute myeloid leukemia. Securing funding is crucial for a clinical-stage biotech company like Moleculin to continue progressing its pipeline of potential new cancer and antiviral therapies.

The details

Under the agreements, certain warrant holders have agreed to immediately exercise warrants to purchase up to an aggregate of 2,122,652 shares of Moleculin's common stock at an exercise price of $3.90 per share. In consideration, the company will issue new unregistered warrants to purchase up to 6,367,956 additional shares at an exercise price equal to the lesser of $3.90 per share or the lowest volume weighted average price over the next five trading days. The transaction is expected to close on or about February 20, 2026.

• The warrant exercise agreements were announced on February 19, 2026.
• The transaction is expected to close on or about February 20, 2026.

What’s next

The company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.